COVID-19 pill could be available later this year: Pfizer CEO
(HealthDay)—A pill to treat COVID-19 is being developed by Pfizer and could be available by the end of the year, company CEO Albert Bourla says.
Apr 30, 2021
0
46
(HealthDay)—A pill to treat COVID-19 is being developed by Pfizer and could be available by the end of the year, company CEO Albert Bourla says.
Apr 30, 2021
0
46
A compound in avocados may ultimately offer a route to better leukemia treatment, says a new University of Guelph study.
Apr 29, 2021
0
52
Developing new drugs to treat diseases can take years or decades—time that we do not have when it comes to treating patients with COVID-19. So Northeastern researchers came up with another way to discover treatments for ...
Apr 28, 2021
0
83
Human clinical trials have begun on a new vaccine candidate that may protect against not only SARS-CoV-2, the virus that causes COVID-19, but against at least two of the variants emerging around the world. The development ...
Apr 21, 2021
0
5
With more than 125 million people infected and nearly 3 million dead, the COVID-19 pandemic has disrupted the world in inconceivable ways. Adding to the challenge is that the patient condition varies widely, from the asymptomatic ...
Apr 19, 2021
0
22
An experimental antiviral drug can significantly decrease levels of the virus causing COVID-19 and the damage it causes in the lungs, according to new research.
Apr 16, 2021
0
325
Scientists from Queen Mary University of London, funded by the charity Brain Tumor Research, have found a new way to starve cancerous brain tumor cells of energy in order to prevent further growth.
Apr 12, 2021
2
186
Researchers at the Francis Crick Institute have found that blocking a specific protein could increase tumor sensitivity to treatment with PARP inhibitors. Their work published in Science , suggests combining treatments could ...
Apr 8, 2021
0
54
New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.
Apr 6, 2021
0
111
A gene called KRAS is one of the most commonly mutated genes in all human cancers, and targeted drugs that inhibit the protein expressed by mutated KRAS have shown promising results in clinical trials, with potential approvals ...
Apr 6, 2021
1
35